A Phase 2 interventional study of VX-152 and TEZ/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 28th largest by enrollment, is one of 6 that started in 2016, is one of 8 in phase 2, and was the 12th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 6 started in 2016.
This study's enrollment of 80 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 55th largest by enrollment of the 116 interventional ones that give a count, is one of 15 that started in 2016, is one of 21 in phase 2, and was the 58th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF), or who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have an eligible CFTR genotype:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: VX-152 · Drug: TEZ/IVA · Drug: IVA
Drug: VX-152 · Drug: TEZ/IVA · Drug: IVA
Drug: VX-152 · Drug: TEZ/IVA · Drug: IVA
Drug: TEZ/IVA · Drug: IVA · Drug: Placebo
Drug: VX-152 · Drug: TEZ/IVA · Drug: IVA
Drug: TEZ/IVA · Drug: IVA · Drug: Placebo
Drug: VX-152 · Drug: TEZ/IVA · Drug: IVA
Tablet for oral administration.
Drug pages: Tezacaftor · Ivacaftor
Fixed-dose combination tablet for oral administration.
Also known as: VX-661/VX-770, Tezacaftor/Ivacaftor
Tablet for oral administration.
Also known as: VX-770, Ivacaftor
Placebo matched to VX-152.
Placebo matched to VX-152/TEZ/IVA triple combination (TC).
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 Through Safety Follow-up Visit (Up to Day 43 for Part 1 and Day 71 for Part 2)
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 15 for Part 1 and Part 2 Cohort 2A
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline at Day 15
Absolute Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline Through Day 29
Absolute Change in Sweat Chloride Concentrations at Day 15 for Part 1 and Part 2 Cohort 2A
Sweat samples were collected using an approved collection device.
Time frame: From Baseline at Day 15
Absolute Change in Sweat Chloride Concentrations Through Day 29 for Part 2 Cohort 2B
Sweat samples were collected using an approved collection device.
Time frame: From Baseline Through Day 29
Relative Change in ppFEV1 at Day 15 for Part 1 and Part 2 Cohort 2A
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline at Day 15
Relative Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline Through Day 29
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 15 for Part 1 and Part 2 Cohort 2A
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline at Day 15
Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 29 for Part 2 Cohort 2B
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline at Day 29
Pre-dose Plasma Concentration (Ctrough) of VX-152, TEZ, M1-TEZ, IVA, and M1-IVA
Time frame: Pre-dose at Day 8, Day 15 and Day 29
| Milestone | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC |
|---|---|---|---|---|---|---|---|---|
| Started | 8 | 6 | 10 | 10 | 4 | 10 | 7 | 21 |
| Completed | 8 | 6 | 10 | 10 | 4 | 10 | 7 | 21 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| participants | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC |
|---|---|---|---|---|---|---|---|---|
| Participants with TEAEs | 8 | 3 | 7 | 10 | 3 | 6 | 5 | 19 |
| Participants with SAEs | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC |
|---|---|---|---|---|---|---|
| Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 15 for Part 1 and Part 2 Cohort 2A | -0.8 (-4.8 to 3.3) | 5.7 (1.0 to 10.3) | 9.7 (6.1 to 13.3) | 8.0 (4.0 to 12.0) | -1.0 (-9.9 to 7.8) | 7.3 (1.9 to 12.6) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC |
|---|---|---|
| Absolute Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B | -2.2 (-6.6 to 2.1) | 6.5 (4.0 to 9.0) |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC |
|---|---|---|---|---|---|---|
| Absolute Change in Sweat Chloride Concentrations at Day 15 for Part 1 and Part 2 Cohort 2A | -0.1 (-8.4 to 8.3) | -19.5 (-29.1 to -10.0) | -13.6 (-21.4 to -5.8) | -27.5 (-35.0 to -20.1) | 3.5 (-9.2 to 16.2) | -21.3 (-29.5 to -13.1) |
Sweat samples were collected using an approved collection device.
| mmol/L | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC |
|---|---|---|
| Absolute Change in Sweat Chloride Concentrations Through Day 29 for Part 2 Cohort 2B | 1.6 (-6.8 to 10.0) | -22.3 (-27.3 to -17.3) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC |
|---|---|---|---|---|---|---|
| Relative Change in ppFEV1 at Day 15 for Part 1 and Part 2 Cohort 2A | -2.3 (-9.8 to 5.3) | 10.3 (1.6 to 19.0) | 19.0 (12.3 to 25.8) | 14.8 (7.3 to 22.4) | -1.4 (-17.1 to 14.4) | 13.2 (3.7 to 22.7) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC |
|---|---|---|
| Relative Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B | -2.0 (-9.2 to 5.1) | 11.5 (7.4 to 15.7) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC |
|---|---|---|---|---|---|---|
| Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 15 for Part 1 and Part 2 Cohort 2A | -7.6 (-18.6 to 3.4) | 6.6 (-6.0 to 19.1) | 21.8 (12.1 to 31.6) | 18.6 (8.8 to 28.5) | 5.8 (-8.0 to 19.6) | 10.6 (1.9 to 19.2) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC |
|---|---|---|
| Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 29 for Part 2 Cohort 2B | 4.8 (-3.7 to 13.3) | 16.1 (11.2 to 21.0) |
| nanogram per milliliter (ng/mL) | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC |
|---|---|---|---|---|---|---|---|
| Day 8: VX-152 | 167 ± 65.4 | 240 ± 370 | 538 ± 576 | — | 355 ± 287 | — | 463 ± 730 |
| Day 15: VX-152 | 173 ± 72.1 | 278 ± 212 | 804 ± 812 | — | 554 ± 429 | — | 560 ± 657 |
| Day 29: VX-152 | — | — | — | — | — | — | 698 ± 1040 |
| Day 8: TEZ | 2610 ± 1400 | 1500 ± 1140 | 1680 ± 996 | 1900 ± 1730 | 1830 ± 693 | 2010 ± 669 | 1460 ± 1470 |
| Day 15: TEZ | 2450 ± 2000 | 1220 ± 545 | 1180 ± 495 | 1120 ± 135 | 1620 ± 1030 | 1970 ± 1040 | 1050 ± 543 |
| Day 29: TEZ | — | — | — | — | — | 2470 ± 1060 | 1190 ± 422 |
| Day 8: M1-TEZ | 4520 ± 1090 | 3060 ± 1480 | 3490 ± 1640 | 3760 ± 1100 | 4900 ± 1050 | 4980 ± 1450 | 4150 ± 1280 |
| Day 15: M1-TEZ | 4680 ± 1020 | 2890 ± 898 | 3310 ± 1220 | 3430 ± 824 | 4270 ± 1280 | 4420 ± 1810 | 3650 ± 1320 |
| Day 29: M1-TEZ | — | — | — | — | — | 4280 ± 1650 | 3680 ± 742 |
| Day 8: IVA | 779 ± 442 | 522 ± 401 | 545 ± 234 | 702 ± 425 | 610 ± 262 | 953 ± 360 | 434 ± 251 |
| Day 15: IVA | 841 ± 588 | 535 ± 310 | 467 ± 236 | 441 ± 300 | 645 ± 373 | 863 ± 488 | 389 ± 222 |
| Day 29: IVA | — | — | — | — | — | 1010 ± 446 | 468 ± 279 |
| Day 8: M1-IVA | 1590 ± 1050 | 1040 ± 947 | 1330 ± 747 | 1660 ± 1200 | 1470 ± 671 | 1810 ± 665 | 1170 ± 551 |
| Day 15: M1-IVA | 1230 ± 326 | 1200 ± 848 | 1140 ± 550 | 1030 ± 762 | 1510 ± 891 | 1620 ± 760 | 1100 ± 598 |
| Day 29: M1-IVA | — | — | — | — | — | 1890 ± 659 | 1240 ± 705 |
Collected over Day 1 Through Safety Follow-up Visit (Up to Day 43 for Part 1 and Day 71 for Part 2). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo | 0/8 (0%) | 2/8 (25%) | 8/8 (100%) |
| Part 1 Cohort 1A: TC | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 1 Cohort 1B: TC | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Part 1 Cohort 1C: TC | 0/10 (0%) | 1/10 (10%) | 9/10 (90%) |
| Part 2 Cohort 2A: TEZ/IVA | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Part 2 Cohort 2A: TC | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Part 2 Cohort 2B: TEZ/IVA | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Part 2 Cohort 2B: TC | 0/21 (0%) | 0/21 (0%) | 18/21 (85.7%) |
| Event | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC |
|---|---|---|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 1/8 | 0/6 | 0/10 | 1/10 | 0/4 | 0/10 | 0/7 | 0/21 |
| Viral infectionInfections and infestations | 1/8 | 0/6 | 0/10 | 0/10 | 0/4 | 0/10 | 0/7 | 0/21 |
| Event | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC |
|---|---|---|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 3/8 | 0/6 | 1/10 | 0/10 | 0/4 | 1/10 | 3/7 | 5/21 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 2/6 | 2/10 | 1/10 | 0/4 | 0/10 | 0/7 | 3/21 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/8 | 2/6 | 2/10 | 2/10 | 0/4 | 0/10 | 0/7 | 3/21 |
| HeadacheNervous system disorders | 0/8 | 1/6 | 1/10 | 3/10 | 1/4 | 0/10 | 0/7 | 4/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/8 | 0/6 | 3/10 | 1/10 | 1/4 | 1/10 | 0/7 | 6/21 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 1/8 | 1/6 | 2/10 | 1/10 | 0/4 | 1/10 | 1/7 | 6/21 |
| NauseaGastrointestinal disorders | 1/8 | 0/6 | 0/10 | 0/10 | 1/4 | 0/10 | 0/7 | 2/21 |
| GastroenteritisInfections and infestations | 0/8 | 0/6 | 0/10 | 0/10 | 1/4 | 0/10 | 0/7 | 0/21 |
| Muscle strainInjury, poisoning and procedural complications | 0/8 | 0/6 | 0/10 | 0/10 | 1/4 | 0/10 | 0/7 | 0/21 |
| Weight decreasedInvestigations | 0/8 | 0/6 | 0/10 | 0/10 | 1/4 | 0/10 | 0/7 | 0/21 |
| Age, Customized(Participants) | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC | Total |
|---|---|---|---|---|---|---|---|---|---|
| <18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| >=18 and <65 years | 8 | 6 | 10 | 10 | 4 | 10 | 7 | 21 | 76 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 2 | 4 | 3 | 2 | 6 | 4 | 14 | 39 |
| Male | 4 | 4 | 6 | 7 | 2 | 4 | 3 | 7 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 |
| Not Hispanic or Latino | 6 | 6 | 10 | 9 | 4 | 10 | 7 | 21 | 73 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 7 | 5 | 10 | 10 | 4 | 10 | 7 | 21 | 74 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)(Participants) | Part 1: Placebo | Part 1 Cohort 1A: TC | Part 1 Cohort 1B: TC | Part 1 Cohort 1C: TC | Part 2 Cohort 2A: TEZ/IVA | Part 2 Cohort 2A: TC | Part 2 Cohort 2B: TEZ/IVA | Part 2 Cohort 2B: TC | Total |
|---|---|---|---|---|---|---|---|---|---|
| <40 percent | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 4 |
| ≥40 to <70 percent | 5 | 6 | 7 | 4 | 3 | 10 | 5 | 18 | 58 |
| ≥70 to ≤90 percent | 2 | 0 | 1 | 5 | 1 | 0 | 2 | 3 | 14 |
| >90 percent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Jan 2018, 14 months.
Results were first posted in Jan 2021, 3 years after primary completion. A results delay was requested in Jan 2019.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 14 months is close to that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →